News
Merck, the New Jersey-based drug giant, is spending $1 billion on a new Delaware factory to bring production of its ...
Merck has initiated construction of a $1 billion, 470,000-square-foot biologics center of excellence in Wilmington, Delaware.
It will build a Wilmington, Delaware facility dedicated to making its cancer drug, Keytruda, for U.S. patients.
Located at Chestnut Run Innovation & Science Park, the Merck Wilmington Biotech project will comprise laboratory, ...
According to Merck, the total investment is now expected to be over $1 billion, with 500 full-time jobs and 4,000 ...
The firm reported revenues of $15.53 billion and adjusted earnings per share of $2.22, surpassing consensus predictions of ...
Merck CEO Robert Davis spoke about the new state-of-the-art biologics center slated to be based in Wilmington, Delaware that ...
U.S. drugmaker Merck said on Tuesday it is investing $1 billion in a new Delaware plant to expand domestic production as it ...
The Delaware facility will ensure a domestic supply of biologic drugs including the cancer drug Keytruda.
Merck announced on Tuesday that it is investing $1 billion in a new Delaware plant to expand domestic production as it ...
Merck is particularly exposed to the tariff threat, as much of its production of Keytruda takes place at facilities in ...
Merck KGaA struck a $3.9 billion deal for SpringWorks Therapeutics. Novartis plans to acquire Regulus Therapeutics for $800 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback